Philadelphia, PA About Blog The Children's Brain Tumor Tissue Consortium is committed to discovering new cures and better therapies for children
with pediatric brain tumors.
Not exact matches
Frustrated
with the lack of investment in research and drug development devoted to
pediatric brain tumor gliomas, the Kamens decided to take action and launch their foundation.
The Kamens claim the main thing that distinguishes their foundation from other
brain tumor foundations is their focus on
pediatric brain cancer specifically, as well as their close ties
with pharmaceutical and biotech companies working in the fields of immunotherapy and target gene therapy.
He remains a leader in supportive care and research in
pediatric oncology,
with a special focus on neuroblastoma, non-Hodgkin lymphoma, Ewing Sarcoma, acute lymphoblastic leukemia and
brain tumors.
In particular, our
pediatric radiation oncologists at Floating Hospital for Children offer special expertise in the management of
brain tumors, including medulloblastoma,
with a combination of post-operative radiotherapy and multi-agent chemotherapy.
As these compounds are already approved for clinical trails in
pediatric brain tumors, these findings suggest that drugs inhibiting MEK activity could offer a new therapy option for children
with these devastating
tumors.
«Carefully defining the molecular landscape of these
tumor subtypes may guide us in
pediatric precision medicine, to better treat children
with brain tumors,» said Payal Jain, PhD, a postdoctoral researcher at Children's Hospital of Philadelphia (CHOP).
Researchers investigating
pediatric low - grade gliomas (PLGG), the most common type of
brain tumor in children, have discovered key biological differences in how mutated genes combine
with other genes to drive this childhood cancer.
The six
tumors with matched normal DNA harbored 15 somatic mutations on average (range 3 - 31), a mutation rate lower than adult GBM but higher than another
pediatric brain tumor, medulloblastoma.
UT Southwestern's
pediatric neurosurgeons are some of the most gifted neurosurgeons in the country and have, along
with their colleagues in neuro - oncology, radiation oncology, and neuro - radiology, dedicated their lives to the care of children
with brain tumors.
We treat 80 to 100 children
with brain tumors each year, and we established the first
pediatric neuro - oncology program in Texas.
Our team combines patient - centered comprehensive care
with state - of - the - art technology and research to provide the best possible outcomes for
pediatric brain tumor patients.
Our groundbreaking
Pediatric Mi - Oncoseq Program is an internationally known precision oncology program focusing on the genetic analysis of
pediatric cancer patients including in children
with malignant
brain tumors, and determines whether targeted treatments may be available based upon their personalized
tumor genomic sequencing profiles.